Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases

Arthritis Care and Research

Volumn 62, Issue 12, 2010, Pages 3569-3573

  Rekedal, Laura R ^a   Massarotti, Elena ^a   Garg, Rajesh ^a   Bhatia, Radhika ^a   Gleeson, Timothy ^a   Lu, Bing ^a   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOCORTICOID; HEMOGLOBIN A1C; HYDROXYCHLOROQUINE; INSULIN; METHOTREXATE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRONIC MEDICAL RECORD; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; AGE; LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; RHEUMATIC DISEASE; SEX;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYCHLOROQUINE; INSULIN; LINEAR MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; TREATMENT OUTCOME;

EID: 78650050052     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27703     Document Type: Article

References (28)

1. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
2. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A,. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
3. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al, on behalf of the Early Rheumatoid Arthritis Study (ERAS) group. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007; 46: 350-7.
4. Goodson N, Marks J, Lunt M, Symmons D,. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005; 64: 1595-601.
5. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP,. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002; 46: 2010-9.
6. Navarro-Cano G, del Rincon I, Pogosian S, Roldan JF, Escalante A,. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis Rheum 2003; 48: 2425-33.
7. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
8. Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T,. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 2004; 50: 1734-9.
9. Hall FC, Dalbeth N,. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology (Oxford) 2005; 44: 1473-82.
10. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
11. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 2008; 67: 64-9.
12. Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV,. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167-72.
13. Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Avalos I, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum 2008; 58: 2105-12.
14. Dessein PH, Joffe BI,. Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2765-75.
15. Riserus U, Arnlov J, Berglund L,. Long-term predictors of insulin resistance: role of lifestyle and metabolic factors in middle-aged men. Diabetes Care 2007; 30: 2928-33.
16. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-14.
17. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK,. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1495-8.
18. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK,. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFα therapy. Scand J Rheumatol 2007; 36: 91-6.
19. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA,. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005; 64: 765-6.
20. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-26.
21. Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: a new job for an old drug? Ann Intern Med 1990; 112: 678-81.
22. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB,. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas: a randomized trial. Diabetes Res Clin Pract 2002; 55: 209-19.
23. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298: 187-93.
24. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB,. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2447-53.
25. Chapelle JP, Teixeira J, Maisin D, Assink H, Barla G, Stroobants AK, et al. Multicentre evaluation of the Tosoh HbA1c G8 analyser. Clin Chem Lab Med 2010; 48: 365-71.
26. Powrie JK, Smith GD, Shojaee-Moradie F, Sonksen PH, Jones RH,. Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. Am J Physiol 1991; 260: E897-904.
27. Emami J, Pasutto FM, Mercer JR, Jamali F,. Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats. Life Sci 1999; 64: 325-35.
28. Garcia-Webb P, Bonser AM,. Insulin binding and degradation in isolated hepatocytes from streptozotocin injected rats. Biochem Biophys Res Commun 1985; 128: 487-93.